Diosmin 600 mg, 60 film-coated tablets
Registration Certificate Holder
VERTEX (Russia)
Dosage form
Medicine - Diosmin
Description
Film-coated tablets
pink, oval, biconvex; on a cross section, the core is grayish-yellow or light yellow.
1 tab.
diosmin 600 mg
Excipients
: microcrystalline cellulose - 241.5 mg, talc - 18 mg, hyprolose (hydroxypropylcellulose) - 13.5 mg, croscarmellose sodium - 13.5 mg, magnesium stearate - 9 mg, colloidal hydrophobic silicon dioxide - 4.5 mg.
Film casing:
[hypromellose - 16.2 mg, talc - 5.4 mg, titanium dioxide - 2.79 mg, macrogol 4000 (polyethylene glycol 4000) - 2.43 mg, red iron oxide dye (iron oxide) - 0.18 mg] or [dry mixture for film coating containing hypromellose ( 60%), talc (20%), titanium dioxide (10.33%), macrogol 4000 (polyethylene glycol 4000) (9%), red iron oxide dye (iron oxide) (0.67%)] - 27 mg.
10 pieces. — cellular contour packages (1) — cardboard packs. 10 pieces. — cellular contour packages (3) — cardboard packs. 10 pieces. — contour cell packaging (6) — cardboard packs. 15 pcs. — cellular contour packages (1) — cardboard packs. 15 pcs. — contour cell packaging (2) — cardboard packs. 15 pcs. — contour cell packaging (4) — cardboard packs. 15 pcs. — contour cell packaging (6) — cardboard packs. 30 pcs. — cellular contour packages (1) — cardboard packs. 30 pcs. — contour cell packaging (2) — cardboard packs. 30 pcs. — cellular contour packages (3) — cardboard packs. 15 pcs. - cans (1) - cardboard packs. 30 pcs. - cans (1) - cardboard packs. 90 pcs. - cans (1) - cardboard packs.
Indications
Varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities, hemorrhoids, microcirculation disorders.
Contraindications for use
Hypersensitivity to diosmin; childhood and adolescence up to 18 years, first trimester of pregnancy, breastfeeding period.
pharmachologic effect
Angioprotective agent, bioflavonoid. It has a venotonic effect, improves lymphatic drainage, improves microcirculation, reduces the adhesion of leukocytes to the venous wall and their migration into paravenous tissue, improves oxygen diffusion and perfusion in the skin tissue, and has an anti-inflammatory effect. Blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.
Dosage regimen
Taken orally. Depending on the indications, the daily dose is 600-1800 mg. The duration of use depends on the indications and treatment regimen.
Side effect
From the digestive system:
often - dyspeptic disorders, incl.
nausea, vomiting, diarrhea, heartburn, constipation; infrequently - colitis. From the side of the central nervous system:
rarely - headache, malaise, dizziness.
Allergic reactions:
rarely - urticaria; frequency unknown - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema (Quincke's edema).
special instructions
Treatment of an acute attack of hemorrhoids is carried out in combination with other drugs.
Use during pregnancy and breastfeeding
Restrictions during pregnancy - With caution. Restrictions when breastfeeding - Contraindicated.
Use is contraindicated in the first trimester of pregnancy (experience of use is limited). Use in the second and third trimesters is possible only as prescribed by a doctor, in cases where the expected benefit of therapy for the mother outweighs the potential risk for the fetus.
Use during breastfeeding is not recommended, because... There is no data on the excretion of diosmin in breast milk.
Experimental
studies
did not reveal a teratogenic effect on the fetus.
Use in children
Restrictions for children - Contraindicated. Use in children and adolescents under 18 years of age is contraindicated.
Venotonic SP (Diosmin and Hesperidin 1000 mg tab. vol. No. 30)
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Description
VENOTONIK SP “DIOSMIN AND HESPERIDIN 1000 mg” is a complex of DIOSMIN and HESPERIDIN, which help maintain the functional activity of the venous and lymphatic systems of the human body.
Compound
Active substances (a mixture of diosmin and hesperidin (9:1)), excipients (anti-caking agent (microcrystalline cellulose)), shell (hydroxypropyl methylcellulose, polyethylene glycol, dyes (aluminum varnish based on quinoline yellow, sunset yellow, titanium dioxide, iron yellow oxide)), excipients (anti-caking agents (magnesium stearate, silicon dioxide), gelatin). Content of active substances in a daily dose (1 tablet) Active substances Content in one tablet HESPERIDIN 100 mg DIOSMIN 900 mg
Description and release form
Tablets are cylindrical or biconvex, or biconvex round oblong, weighing 1.6 g. The color of the tablets ranges from flesh to orange. 30 tablets. There are 3 blisters in a cardboard pack.
Application area
It is recommended as an additional source of hesperidin, contains diosmin, to maintain the functional activity of the venous and lymphatic systems of the body. Diosmin and hesperidin increase the tone of veins and reduce their distensibility. Also, a positive effect is manifested in improving the permeability of capillaries and strengthening them. The use of drugs based on these components helps to get rid of venous stagnation. Diosmin and hesperidin help relieve the feeling of heaviness and fatigue in the legs and reduce swelling of the lower extremities.
Recommendations for use
Take orally for persons over 18 years of age, 1 tablet per day, with meals.
Duration of admission
The course of treatment is 1 - 2 months. After 2-3 months the course can be repeated.
Contraindications
Hypersensitivity to product components, pregnancy and breastfeeding. Contains dyes that may have a negative effect on the activity and attention of children. It is recommended to consult a doctor before use.
Storage conditions
In a place protected from direct sunlight and out of reach of children, at a temperature not exceeding 25°C and a relative humidity of not more than 80%. Do not use after expiration date. Shelf life: 3 years.
Terms of sale
Through a pharmacy chain and specialized stores, departments of a retail chain. There is no nutritional or energy value. Certificate of state registration and date of issue No. BY.70.06.01.003.E.000179.01.19 dated 01/04/2019. TU 10.89.19-019-90692556-2018.
Manufacturer / organization authorized to accept complaints from consumers
Pharmaceutical Factory LLC, Russia, 440066, Penza, Stroiteley Ave., 30, office.
127, tel., 8-800-600-15-86. Production address: Pharmaceutical Factory LLC, Russia, 440068, Penza, st. Ryabova, 31. Ordered by: LLC "SP", Russian Federation, 143912, Moscow region, Balashikha, Entuziastov highway, Western communal zone, property 1A, office 1. Dietary supplement to food. Not a medicine.
Venarus (diosmin+hesperedin) tablets 500 mg No. 30
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Hesperidin + Diosmin
Compound
Film-coated tablets Active substances: diosmin 0.45 g, hesperidin 0.05 g Excipients: core - gelatin, magnesium stearate, MCC, starch, sodium glycolate, talc; shell - polyethylene glycol 6000, magnesium stearate, hydroxypropyl methylcellulose, sodium lauryl sulfate, titanium dioxide, red iron oxide, yellow iron oxide Description of the dosage form Orange-pink, biconvex, oblong-shaped tablets with rounded ends, scored. The cross section shows two layers. Release form Film-coated tablets, 500 mg. 10 or 15 coated tablets in blister packs. 2, 3, 4, 6, 7, 8, 9 blister packs are placed in a cardboard pack.
Pharmacological properties
Venotonic, angioprotective. Pharmacodynamics Has angioprotective and venotonic effects. Reduces the distensibility of veins, increases their tone and reduces venous stagnation; reduces permeability and fragility of capillaries and increases their resistance; improves microcirculation and lymphatic drainage. When used systematically, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature. Pharmacokinetics The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine. T1/2 - 11 hours. The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.
Indications for use
• Treatment of symptoms of venous-lymphatic insufficiency: pain, cramps of the lower extremities, a feeling of heaviness and fullness in the legs, “fatigue” of the legs. • Treatment of manifestations of venous-lymphatic insufficiency: edema of the lower extremities, trophic changes in the skin and subcutaneous tissue, venous trophic ulcers. • Symptomatic treatment of acute and chronic hemorrhoids.
Contraindications
• Hypersensitivity to the components of the drug; • Lactation period. Use during pregnancy and lactation Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of any side effects when using the drug by pregnant women. Due to the lack of data regarding the excretion of the drug into breast milk, taking the drug is not recommended for nursing women.
Mode of application
Inside. The recommended dose for venous-lymphatic insufficiency is 2 tablets per day (in one or two doses): morning, afternoon and/or evening, during meals. The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated. The recommended dose for acute hemorrhoids is 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days. The recommended dose for chronic hemorrhoids is 2 tablets per day with food.
Side effect
The frequency of adverse reactions is presented as follows: very often (≥1/10 cases), often (≥1/100 and From the central nervous system: Rarely - dizziness, headache, general malaise; frequency unknown - convulsions. From the gastrointestinal tract: Often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; frequency unknown - abdominal pain. From the respiratory system, chest and mediastinal organs: Frequency unknown - sore throat, chest pain. From the skin: Rarely - rash, itching, urticaria; frequency unknown - allergic dermatitis, hyperemia, isolated swelling of the face, lips, eyelids, in exceptional cases - angioedema. If any of the adverse reactions indicated in the description are aggravated, or the patient notices other adverse reactions not listed in the description, you should report this to your doctor.
Overdose
No cases of overdose have been described. In case of overdose of the drug, you should immediately seek medical help.
Interaction
Not noted. You should inform your doctor about all medications you are taking.
special instructions
In case of exacerbation of hemorrhoids, the prescription of this drug does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If symptoms do not disappear after the recommended course of therapy, a proctological examination should be performed and the therapy used should be reconsidered. In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, as well as reducing excess body weight. Walking and, in some cases, wearing special stockings helps improve blood circulation. Impact on the ability to drive vehicles, operate machinery and engage in other activities that require increased concentration. Does not affect.
Diosmin Tablets, box, 30 pcs, 600 mg, for oral administration, film-coated
Pharmacological properties
Pharmacodynamics
Diosmin is a benzpyrone derivative. Belongs to the group of bioflavonoids. It has a phlebotonic effect (reduces the distensibility of veins, increases the tone of veins (dose-dependent effect), reduces venous stagnation), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases the resistance of capillaries ( dose-dependent effect), reduces their permeability), reduces the adhesion of leukocytes to the venous wall and their migration into paravenous tissues, improves oxygen diffusion and perfusion in the skin tissue, and has an anti-inflammatory effect.
Strengthens the vasoconstrictor effect of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane. It has been shown that diosmin reduces the plasma levels of enzymes responsible for the metabolism of mucopolysaccharides in the venous wall.
In clinical studies, diosmin reduced venous capacity and venous congestion volume (as measured by plethysmography), decreased mean pressure in the deep and superficial veins of the legs (as measured by Doppler ultrasound), and increased systolic and diastolic blood pressure in patients with postoperative orthostatic hypotension. Pharmacokinetics Absorption Rapidly absorbed from the gastrointestinal tract, detected in blood plasma 2 hours after administration. The bioavailability of diosmin after oral administration is approximately 40-57.9%.
In the intestine, diosmin is transformed by intestinal microflora into diosmetin, hippuric and benzoic acid. Distribution The maximum concentration in blood plasma is achieved 5 hours after administration. Diosmin is evenly distributed and accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities, and to a lesser extent in the kidneys, liver, lungs and other tissues.
The distribution volume is 62.1 l. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum by the ninth hour after administration and persists for 96 hours. Metabolism Diosmin is metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid.
Diosmin metabolites are excreted primarily by the kidneys in the form of conjugates with glucuronic acid.
Excretion 79% of taken diosmin is excreted by the kidneys, through the intestines - 11%, with bile - 2.4%. Enterohepatic circulation of diosmin is noted. After taking radiolabeled diosmin, approximately 86% is excreted by the kidneys and intestines within 48 hours.
